SURVYR

WST

West Pharmaceutical Services, Inc.
$398.29
+$3.56 (0.90%)Oct 27 close
Health CareS&P 500 CompareTechnicals
1M3M6M1Y2Y
-22%-7%+9%+24%+39%Oct 2025Oct 2026Apr 202652w high $398.6752w low $223.83
WSTSPY
Wall St. Highest PT $459.00 (+15.2%) Wall St. Avg PT $416.40 (+4.5%)
$231$291$352$412$473POC $273Hi $459Avg $416
Underwater Drawdown %Max DD -19.5%Current 0.0%
0.0%-19.5%
Relative Strength vs SPY+25.6% vs SPYOutperforming
+29%0%-29%
1W
+$9.51 (2.45%)
1M
+$27.85 (7.52%)
3M
+$61.51 (18.26%)
6M
+$106.57 (36.53%)
YTD
+$123.79 (45.10%)
1Y
+$111.96 (39.10%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Strong Buy
16 analysts · mean score 1.38
1 = Strong Buy · 5 = Sell
Strong Buy319%
Buy1275%
Hold00%
Underperform00%
Sell16%
Wall Street consensus
Analyst price targets
Current price$398.29
Average target$416.40
+$18.11 (+4.5%) upsideaverage target vs current price
CurrentAverageMedian
Low$340.00
Median$412.00
High$459.00
12-month Wall Street target range
Recent analyst rating changes · 30
Reiterated
2026-10-13 · TD Cowen reiterated Buy on WST
Reiterated
2026-10-07 · Barclays reiterated Overweight on WST
Upgrade
2026-09-22 · Morgan Stanley upgraded WST from Equal-Weight to Overweight
Reiterated
2026-09-09 · UBS reiterated Buy on WST
Reiterated
2026-08-03 · Citigroup reiterated Buy on WST
Reiterated
2026-07-27 · Evercore ISI Group reiterated Outperform on WST
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$28.0B
P/E (last 12 months)51.0
P/E (next 12 months, estimated)39.9
52-week range$223.83 – $398.67
Revenue growth (latest quarter vs a year ago)+13.8%
Dividend yield0.26%
Analyst consensusStrong Buy (15)
Average analyst price target$416.40 (+5%)

What they do

West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems.

Healthcare · Medical Instruments & Supplies
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

Momentum
66th percentile in sector
B
12-1 return: +31.9%
Percentile within its GICS sector across the S&P 1500.
Growth
71st percentile in sector
B
Revenue growth (YoY): +13.8%
Percentile within its GICS sector across the S&P 1500.
Value
12th percentile in sector
D-
Forward E/P: 2.6% · EBITDA/EV: 3.4%
Percentile within its GICS sector across the S&P 1500.
Profitability
72nd percentile in sector
B+
Profit margin: +17.0% · Return on equity: +19.1%
Percentile within its GICS sector across the S&P 1500.
Revisions
Not enough data yet
–
EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
ranked 58 of 360 · Composite (0-1) 0.7
 Momentum Top 15
ranked 136 of 499 · 12-month momentum 30.4%
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

WST earningsNext report in 2 days
Next report · quarter Sep 2026
Thu Oct 29, 2026Before the open
EPS consensus$2.20 range $2.16–$2.23
Revenue consensus$826.5M 12 analysts
Last 4 quarters · EPS vs estimate
Jul 23, 2026$2.37est $2.08+13.9%Above estimates
Apr 23, 2026$2.13est $1.68+27.1%Above estimates
Feb 12, 2026$2.04est $1.83+11.5%Above estimates
Oct 23, 2025$1.96est $1.71+14.6%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · report time: Nasdaq earnings calendar · refreshed 2026-10-27 18:23:52 ET
24-1025-0225-0425-0725-1026-0226-0426-070.002.37
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$872.3M+13.8%
2026-03-31$844.9M–
2025-12-31$805.0M–
2025-09-30$804.6M–
2025-06-30$766.5M–

Recent dividends

2026-07-29: $0.220 · 2026-04-29: $0.220 · 2026-01-28: $0.220 · 2025-11-12: $0.220 · 2025-07-30: $0.210 · 2025-04-30: $0.210 · 2025-02-07: $0.210 · 2024-11-13: $0.210

News & catalysts

More news
West Pharmaceutical Services (WST) files 8-K: material agreement
SEC 8-K · Oct 26
Rating changes
Reiterated
2026-10-13 · TD Cowen reiterated Buy on WST
Reiterated
2026-10-07 · Barclays reiterated Overweight on WST
Upgrade
2026-09-22 · Morgan Stanley upgraded WST from Equal-Weight to Overweight
Reiterated
2026-09-09 · UBS reiterated Buy on WST
Reiterated
2026-08-03 · Citigroup reiterated Buy on WST
Reiterated
2026-07-27 · Evercore ISI Group reiterated Outperform on WST

Third-party analyst actions, not SURVYR.'s views. All rating changes

Insider trades
Favorite Annette F
Sr. VP & Chief HR Officer · 2026-09-15
Sell
$921.3K
Favorite Annette F
Sr. VP & Chief HR Officer · 2026-09-14
Sell
$887.5K
Favorite Annette F
Sr. VP & Chief HR Officer · 2026-09-11
Sell
$862.5K
Favorite Annette F
Sr. VP & Chief HR Officer · 2026-09-08
Sell
$852.0K
Favorite Annette F
Sr. VP & Chief HR Officer · 2026-09-08
Sell
$960.4K
Favorite Annette F
Sr. VP & Chief HR Officer · 2026-09-08
Sell
$960.1K
None
None · None
Sell
–
None
None · None
Sell
–
None
None · None
Sell
–

Stats refreshed 2026-10-27 18:23:52 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026